Samuel Stone
Family Medicine · Chester, SCNPI 1063426955
Payments from drug & device makers
Across 92 payments — averaging $14.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$203
- Boehringer Ingelheim$171
- Amgen$124
- AstraZeneca$110
- Pfizer$94
- Takeda Pharmaceuticals U.S.A., Inc.$83
- plus $534 from 19 others
What the payments were for
- Food & beverage$1,18590%
- Education$13310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $203 |
| Boehringer Ingelheim | 5 | $171 |
| Amgen | 7 | $124 |
| AstraZeneca | 8 | $110 |
| Pfizer | 6 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $83 |
| GSK | 5 | $64 |
| Irhythm Technologies, Inc. | 1 | $56 |
| Sunovion Pharmaceuticals Inc. | 3 | $55 |
| Novartis | 3 | $49 |
| Grifols USA, LLC | 3 | $46 |
| Merck | 3 | $35 |
| Bayer | 2 | $31 |
| Aytu Biopharma, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Radius Health, Inc. | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $24 |
| Inari Medical, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Mylan Specialty L.p. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Genentech USA, Inc. | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
| Prugen, Inc. Pharmaceuticals | 2 | $9 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$1,318 in reported general payments places this provider in the 65th percentile of 2,153 family medicine providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 434 | $297,375 |
| OzempicSemaglutide | 193 | $245,094 |
| JardianceEmpagliflozin | 240 | $161,704 |
| JanuviaSitagliptin Phosphate | 148 | $117,942 |
| FarxigaDapagliflozin Propanediol | 156 | $105,893 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 136 | $89,894 |
| LinzessLinaclotide | 120 | $82,038 |
| RybelsusSemaglutide | 49 | $65,938 |
| XareltoRivaroxaban | 65 | $57,675 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $57,522 |
| TrulicityDulaglutide | 31 | $49,847 |
| XifaxanRifaximin | 14 | $43,766 |
| MyrbetriqMirabegron | 77 | $43,178 |
| Repatha SureclickEvolocumab | 31 | $36,453 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $33,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $203 | $311,032242 claims |
| PfizerEliquis | $94 | $297,375434 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $110 | $216,413362 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $171 | $190,821288 claims |
| MerckJanuvia, Janumet, Janumet Xr | $35 | $177,829233 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $12 | $70,42850 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $64 | $46,78974 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $43,17877 claims |
| BayerKerendia | $31 | $21,33934 claims |
| AmgenProlia | $124 | $19,05112 claims |
| NovartisEntresto | $49 | $16,29021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Chester
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.